A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis

2011 ◽  
Vol 90 (6) ◽  
pp. 828-835 ◽  
Author(s):  
J W Mandema ◽  
D H Salinger ◽  
S W Baumgartner ◽  
M A Gibbs
2017 ◽  
Vol 43 (9) ◽  
pp. 1428-1440 ◽  
Author(s):  
Lei Ren ◽  
Peng Guo ◽  
Qiao-Mei Sun ◽  
Hong Liu ◽  
Yu Chen ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Xia Feng ◽  
Xizhu Xu ◽  
Yanjun Shi ◽  
Xuezhen Liu ◽  
Huamin Liu ◽  
...  

Background. Extensive studies have been carried out to investigate the association between obesity and the risk of rheumatoid arthritis (RA); however, the results of the current reported original studies remain inconsistent. This study aimed to clarify the relationship between body mass index and rheumatoid arthritis by conducting an updated overall and dose-response meta-analysis. Methods. The relevant literature was searched using the PubMed and Embase databases (through 20 September 2018) to identify all eligible published studies. Random-effect models and dose-response meta-analyses were used to estimate the pooled risk ratio (RR) with a 95% confidence interval (CI). Subgroup analyses were also conducted based on the characteristics of the participants. Sensitivity analyses and publication bias tests were also performed to explore potential heterogeneity and bias in the meta-analysis. Results. Sixteen studies that included a total of 406,584 participants were included in the meta-analysis. Compared to participants with normal weight, the pooled RRs of rheumatoid arthritis were 1.12 (95% CI, 1.04-1.20) in overweight and 1.23 (95% CI, 1.09-1.39) in obese participants. There was evidence of a nonlinear relationship between body mass index (BMI) and RA (P  for nonlinearity less than 0.001 in the overall meta-analysis, P for nonlinearity=0.025 in the case-control studies, P for nonlinearity=0.0029 in the cohort studies). No significant heterogeneity was found among studies (I2=10.9% for overweight and I2=45.5% for obesity). Conclusion. The overall and dose-response meta-analysis showed that increased BMI was associated with an increased risk for rheumatoid arthritis, which might present a prevention strategy for the prevention or control of rheumatoid arthritis. The nonlinear relationship between BMI and RA might present a personal prevention strategy for RA.


2021 ◽  
Author(s):  
WeiWei Chen ◽  
Ke Liu ◽  
Qing Su ◽  
Xinxian Sang ◽  
Yihan Hu ◽  
...  

Abstract Objective: Findings from previous observational studies on the association between red meat intake and risk of rheumatoid arthritis (RA) are inconsistent. Therefore, we aimed to evaluate the impact of red meat intake on the incidence of RA by meta-analysis.Methods: PubMed and Web of Science were searched for eligible observational studies regarding the association between red meat intake and the risk of RA until June 30, 2021. Risk estimates with corresponding 95% confidence interval (95% CI) were pooled. Subgroup analysis and meta-regression analysis were performed to explore the potential sources of heterogeneity. Sensitivity analysis and publication bias test were also carried out.Results: A total of eleven studies were selected, involving 4 cohort studies with 5 203 identified cases from 349 776 individuals and 7 case-control studies with 3 762 cases and 6 856 controls. The pooled risk estimate of RA risk was 0.94 (95% CI: 0.77 to 1.15) for ever versus non/occasional red meat intake, while high dose of red meat intake increased the risk of RA (OR: 1.26, 95% CI: 1.07 to 1.50) in the categorical meta-analysis. Dose-response meta-analysis suggested a non-linear dose-response relationship between red meat intake and RA (P=0.028). Red meat intake was found to be a risk factor of RA when the dose ranged from 96 to 166 g/day.Conclusion: High dose of red meat intake could increase the risk of RA. Mechanistic studies are warranted to clarify the aetiologic pathways through which high dose of red meat intake may promote RA.


2011 ◽  
Vol 152 (23) ◽  
pp. 919-928 ◽  
Author(s):  
Valentin Brodszky

The therapy of rheumatoid arthritis has been changed by biological treatments. Their efficacy was evaluated in several randomized controlled trials. These trials were different in patient characteristics and the administration regimen. Placebo was the control and direct comparison of biological treatments is missing. Objectives: In the present study the efficacy of biological treatments in patients with rheumatoid arthritis was compared based on the randomized controlled trials available in the literature. A meta-analysis was conducted and meta-regression was used to explore the relationship between disease characteristic variables and observed efficacy. Results: The related scientific literature is broad. Thirty two trials involving 18,500 patients were included into the current meta-analysis. The relative odds ratios of biological treatments compared to placebo varied between 3.6 and 20.0, and between 6.4 and 35.5 in case of monotherapy and combination with non-biological therapy, respectively. Disease duration and added non-biological therapy were in positive relationship with relative efficacy. More severe disease resulted smaller relative effect. Conclusions: The results show that the efficacy of biological treatments is similar. The relative efficacy worsens with more severe disease and improves with disease duration. Orv. Hetil., 2011, 152, 919–928.


2014 ◽  
Vol 16 (5) ◽  
Author(s):  
Daniela Di Giuseppe ◽  
Alessio Crippa ◽  
Nicola Orsini ◽  
Alicja Wolk

2014 ◽  
Vol 16 (2) ◽  
pp. R61 ◽  
Author(s):  
Daniela Di Giuseppe ◽  
Andrea Discacciati ◽  
Nicola Orsini ◽  
Alicja Wolk

Sign in / Sign up

Export Citation Format

Share Document